Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601177 | 0.89 | LPL (0.47) | LPLLIPGSNCAMAOAMAOB | |
| SCHEMBL7606230 | 0.82 | LIPG (0.42) | LPLLIPGSNCADGAT1IRAK4 | |
| SCHEMBL9881587 | 0.82 | LIPG (0.42) | LPLLIPGSNCADGAT1IRAK4 | |
| SCHEMBL12120011 | 0.78 | LPL (0.48) | LPLLIPGSNCAIRAK4 | |
| SCHEMBL12120013 | 0.77 | LPL (0.47) | LPLLIPGSNCAIRAK4 | |
| SCHEMBL2756805 | 0.77 | LPL (0.50) | LPLLIPG | |
| SCHEMBL10022819 | 0.74 | LPL (0.40) | LPLLIPGIRAK4 | |
| SCHEMBL12510072 | 0.72 | LIPG (0.47) | LPLLIPG | |
| SCHEMBL400579 | 0.72 | LIPG (0.51) | LPLLIPGMAOAMAOBDGAT1 | |
| SCHEMBL12230674 | 0.71 | LPL (0.40) | LPLLIPGEGFRIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010065674-A9 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | LPL 458/4885LIPG 1401/4885SNCA 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.